Savolitinib

Drug Profile

Savolitinib

Alternative Names: AZD-6094; HMP-504; HMPL-504; Volitinib

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Hutchison MediPharma
  • Developer AstraZeneca; Hutchison MediPharma; National Cancer Institute (USA); Samsung Medical Center
  • Class Antineoplastics; Imidazoles; Pyrazines; Pyrazoles; Pyridines; Small molecules; Triazines; Triazoles
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Adenocarcinoma; Non-small cell lung cancer; Renal cell carcinoma
  • Phase I Gastric cancer; Solid tumours

Most Recent Events

  • 02 Aug 2016 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO), Taiwan (PO), South Korea (PO), Japan (PO)
  • 02 Aug 2016 Hutchison MediPharma completes a phase I trial in Non-small cell lung cancer in China
  • 02 Aug 2016 Hutchison MediPharma plans a phase II trial for Non-small cell lung cancer in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top